We propose to create an Interdisciplinary Research Consortium (IRC) that will transform the process of drug discovery by integrating novel approaches from genomics, chemistry, imaging and computational science. Our approach is to augment the now traditional approach of target-based screening so that drugs can be developed for situations where evidence points not to a single protein, but rather to a biological process involving many proteins, or an alteration in the state of the cell. With this goal, we propose the pursue the following hypotheses: 1) that live cell screens based on gene-expression signatures (GE-HTS) and quantitative high-throughput live cell imaging (LCI-HTS) can be developed as a primary route to discovering new drugs, and 2) that when combined with novel approaches from Component B (Discovery Pipeline) and Component C (Target ID), these projects will support the discovery of potent and safe drugs with novel mechanisms of action. In order to test these hypotheses and drive the development of new approaches to drug development, Component D will apply the capabilities developed in Component B (Discovery Pipeline) and Component C (Target ID) to six demonstration projects in three areas: 1) well-credentialed genes and pathways that are highly relevant to human disease, and yet to date have failed to yield successful drugs;2) based on knowledge of effective drugs in the clinic, and 3) pathways newly identified in vivo by human genetics as playing causal roles in poorly treated diseases. Each of the six demonstration projects will proceed through four stages: 1) development of cell-based assays, 2) screening for small-molecule leads, 3) identification of the target and medicinal chemistry to optimize the lead compounds, and 4) evaluating efficacy and toxicity using in vivo animal models of disease. In summary, driven by our evaluation of the limitations and opportunities offered by traditional and novel approaches to drug development, and combining the interdisciplinary approaches described in Component B (Discovery Pipeline) and Component C (Target ID) with disease-specific expertise in each of these six demonstration projects, Component D aims to validate a new paradigm for drug discovery, and make significant headway in discovering new small molecules for the treatment of important human diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Linked Research project Grant (RL1)
Project #
6RL1GM084437-03
Application #
7661464
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Fabian, Miles
Project Start
2007-09-30
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$1,185,500
Indirect Cost
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Yu, Channing; Mannan, Aristotle M; Yvone, Griselda Metta et al. (2016) High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34:419-23
Chou, Danny Hung-Chieh; Vetere, Amedeo; Choudhary, Amit et al. (2015) Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc 137:7929-34
Dan?ík, Vlado; Carrel, Hyman; Bodycombe, Nicole E et al. (2014) Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses. J Biomol Screen 19:771-81
Frumm, Stacey M; Fan, Zi Peng; Ross, Kenneth N et al. (2013) Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol 20:713-25
Schenone, Monica; Dan?ík, Vlado; Wagner, Bridget K et al. (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9:232-40
Mulrooney, Carol A; Lahr, David L; Quintin, Michael J et al. (2013) An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries. J Comput Aided Mol Des 27:455-68
Hartwell, Kimberly A; Miller, Peter G; Mukherjee, Siddhartha et al. (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9:840-848
Taipale, Mikko; Krykbaeva, Irina; Whitesell, Luke et al. (2013) Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol 31:630-7
Gerard, Baudouin; Lee 4th, Maurice D; Dandapani, Sivaraman et al. (2013) Synthesis of stereochemically and skeletally diverse fused ring systems from functionalized C-glycosides. J Org Chem 78:5160-71
Lowe, Jason T; Lee 4th, Maurice D; Akella, Lakshmi B et al. (2012) Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J Org Chem 77:7187-211

Showing the most recent 10 out of 29 publications